Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
Belli S, Esposito D, Allotta A, Servetto A, Ciciola P, Pesapane A, Ascione CM, Napolitano F, Di Mauro C, Vigliar E, Iaccarino A, De Angelis C, Bianco R, Formisano L.
Belli S, et al. Among authors: vigliar e.
NPJ Breast Cancer. 2023 May 31;9(1):48. doi: 10.1038/s41523-023-00556-9.
NPJ Breast Cancer. 2023.
PMID: 37258566
Free PMC article.